Company Filing History:
Years Active: 2019
Title: Marie-Caroline Germa: Innovator in Phosphatidylinositol 3-Kinase Inhibitors
Introduction
Marie-Caroline Germa is a notable inventor based in Croissy sur Seine, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatment methods for proliferative diseases. Her work exemplifies the intersection of scientific research and practical application in medicine.
Latest Patents
Marie-Caroline Germa holds a patent for a "Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor." This invention relates to methods of treating or preventing a proliferative disease in patients by orally administering a therapeutically effective amount of a specific compound. The regimen involves administering the compound for at least two five-consecutive day cycles, with a break of about two to three days between cycles. This innovative approach aims to enhance the efficacy of treatment while minimizing potential side effects.
Career Highlights
Marie-Caroline Germa is associated with Novartis AG, a leading global healthcare company. Her work at Novartis has allowed her to collaborate with other talented professionals in the field, contributing to advancements in medical treatments and therapies.
Collaborations
Some of her notable coworkers include Emmanuelle Di Tomaso and Cristian Massacesi. Their collaborative efforts have played a crucial role in the development of innovative pharmaceutical solutions.
Conclusion
Marie-Caroline Germa's contributions to the field of pharmaceuticals, particularly through her patent on phosphatidylinositol 3-kinase inhibitors, highlight her role as a leading innovator. Her work continues to impact the treatment of proliferative diseases, showcasing the importance of innovation in healthcare.